title: Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.
abstract: The blockade of immunological checkpoints has been successfully employed for the treatment of various solid neoplasms including melanoma, mesothelioma, non-small cell lung carcinoma, and renal cell carcinoma. A recent study indicates that the vast majority of patients with advanced, heavily pretreated Hodgkin's lymphoma (HL) also respond to a monoclonal antibody targeting programmed cell death 1 (PDCD1, best known as PD-1). Thus, checkpoint blockers may soon become part of our therapeutic armamentarium against hematological tumors. This would be particularly important as it would spare (at least some) patients the deleterious toxic effects of combinatorial chemotherapies and bone marrow transplantation. We anticipate that the realm of immunotherapy will eventually conquer vast portions of the territory that now belongs to hematological malignancies.
authors.affiliation: Equipe 11 labellisée Ligue contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; INSERM , U1138 ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP ; Paris, France.
authors.forename: Guido
authors.initials: G
authors.lastname: Kroemer
authors.affiliation: Equipe 11 labellisée Ligue contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; INSERM , U1138 ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Galluzzi
keywords: CTLA4; PD-L1; immunostimulatory monoclonal antibodies; ipilimumab; pembrolizumab; pidilizumab